Selected article for: "death risk and present study"
Author: Jun Fei; Lin Fu; Ying Li; Hui-Xian Xiang; Ying Xiang; Meng-Die Li; Fang-Fang Liu; De-xiang Xu; Hui Zhao
Title: Reduction of lymphocyte at early stage elevates severity and death risk of COVID-19 patients: a hospital-based case-cohort study
  • Document date: 2020_4_6
    • ID: 8q1veo3q_42
    Snippet: is the (which was not peer-reviewed) The copyright holder for this preprint . and death risk of COVID-19 patients, which explains why the fatality rate was higher in older COVID-19 patients than in younger ones. The present study provides evidence that lymphocyte reduction on admission may be a potential negative prognostic indicator for COVID-19 patients......
    Document: is the (which was not peer-reviewed) The copyright holder for this preprint . and death risk of COVID-19 patients, which explains why the fatality rate was higher in older COVID-19 patients than in younger ones. The present study provides evidence that lymphocyte reduction on admission may be a potential negative prognostic indicator for COVID-19 patients.

    Search related documents:
    Co phrase search for related documents
    • admission reduction and fatality rate: 1, 2, 3, 4
    • admission reduction and lymphocyte evidence: 1
    • admission reduction and lymphocyte evidence provide: 1
    • admission reduction and old patient: 1
    • admission reduction and present study: 1
    • admission reduction and prognostic indicator: 1
    • death risk and fatality rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • death risk and lymphocyte evidence: 1, 2
    • death risk and lymphocyte evidence provide: 1
    • death risk and old patient: 1, 2, 3, 4, 5, 6
    • death risk and present study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • death risk and prognostic indicator: 1, 2, 3, 4, 5, 6
    • death risk and young one: 1
    • fatality rate and old patient: 1, 2, 3, 4
    • fatality rate and present study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • fatality rate and prognostic indicator: 1, 2
    • lymphocyte evidence and present study: 1, 2
    • lymphocyte evidence and prognostic indicator: 1
    • lymphocyte evidence provide and present study: 1